ClinicalTrials.gg
CompletedNCT01360632PolarisUpdated Jan 1, 2016Results posted

Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)

A Phase 3 interventional study of OPC-34712 + ADT and Placebo + ADT in Depressive Disorder, Depression and Depressive Disorder, Major, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 71 sites in 7 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-01-01.

Primary conditionDepressive Disorder, MajorRegistry: Depressive DisorderReclassifiedWhy we changed it
Registry
Depressive Disorder — the first condition term the registry derived for this study.
ClinicalTrials.gg
Depressive Disorder, Major
Why
  1. The study's listed conditions name Depressive Disorder, Major, a narrower term within Depressive Disorder.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,539
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 24 studies testing brexpiprazole in Depressive Disorder, Major — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Depressive Disorder, Major.

Enrollment
3rd of 24
1,539 · median 189
Started
2011
with 1 other
Phase 3
16 of 24
none open now
Registered
3rd of 24
by date
Lead sponsor
15 of 24
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 24 studies testing brexpiprazole in Depressive Disorder, Major, this one is the 3rd largest by enrollment, is one of 2 that started in 2011, is one of 16 in phase 3, and was the 3rd registered.

Depressive Disorder, Major

3,050 studies on the registry are indexed under Depressive Disorder, Major; 594 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 24 studies testing brexpiprazole in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About brexpiprazole

brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 297 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing brexpiprazole in Depressive Disorder, Major, or all of them as a file.
02

Study summary

To compare the effect of OPC-34712 (brexpiprazole) to the effect of placebo (an inactive substance) as add on treatment to an assigned FDA approved antidepressant treatment (ADT) in patients with Major Depressive Disorder who demonstrate an incomplete response to a prospective trial of the same assigned FDA approved ADT

03

Conditions studied

  • Depressive Disorder
  • Depression
  • Depressive Disorder, Major
  • Mood Disorders
  • Mental Disorders

Keywords

  • OPC-34712
  • brexpiprazole
  • Major Depressive Disorder
  • Adjunctive Treatment
04

In context

Depressive Disorder, Major Reclassified

3,050 studies on the registry are indexed under Depressive Disorder, Major; 594 are open to participants now.

This study's enrollment of 1,539 is above the median of 79 across 2,535 interventional studies indexed under Depressive Disorder, Major.

Browse Depressive Disorder, Major studies →

Lead sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.

Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.

Compared within Depressive Disorder, Major, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Depressive Disorder. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects between 18 and 65 years of age, with diagnosis of major depressive disorder, as defined by criteria
  • The current depressive episode must be equal to or greater than 8 weeks in duration
  • Subjects must report a history for the current depressive episode of an inadequate response to no more than three adequate antidepressant treatments

Exclusion criteria

Exclusion Criteria:

  • Females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving study drug
  • Subjects who report an inadequate response to more than three adequate trials of antidepressant treatments during current depressive episode at a therapeutic dose for an adequate duration
  • Subjects with a current Axis I () diagnosis of: Delirium, dementia, amnestic or other cognitive disorder, Schizophrenia, schizoaffective disorder, or other psychotic disorder, Bipolar I or II disorder
  • Subjects with a current Axis II (DSM-IV-TR) diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal or histrionic personality disorder
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
1,539 participants (actual)

Study arms

  • Experimental
    Phase B

    Drug: OPC-34712 + ADT Drug: Placebo + ADT

    Drug: OPC-34712 + ADT · Drug: Placebo + ADT

  • Placebo comparator
    Phase A

    Drug: Placebo + ADT

    Drug: Placebo + ADT

Interventions

07

What researchers measure

Primary outcomes

  1. Mean Change From the End of Phase A (Week 8 Visit) to Phase B (Week 14 Visit) in the Montgomery-Asberg Depression Rating Scale for the Efficacy Sample Set

    The MADRS was utilized as the primary efficacy assessment of a participant's level of depression. The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place. The MADRS Total Score is the sum of ratings for all 10 items. The possible total scores are from 0 to 60, with higher values indicating worse outcome.

    Time frame: Baseline and Week 14

  2. Mean Change in MADRS Total Score From Baseline End of Week 8 to Week 14 for the Efficacy Sample Per Final Protocol

    The MADRS was utilized as the primary efficacy assessment of a participant's level of depression. The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place. The MADRS Total Score is the sum of ratings for all 10 items. The possible total scores are from 0 to 60, with higher values indicating worse outcome.

    Time frame: Baseline and Week 14

Secondary outcomes

  1. Mean Change From End of Phase A (Week 8 Visit) in MADRS Total Score for Every Study Week Visit in Phase B Other Than Week 14 Visit for the Efficacy Sample Set

    The MADRS was utilized as the primary efficacy assessment of a participant's level of depression. The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place. The MADRS Total Score is the sum of ratings for all 10 items. The possible total scores are from 0 to 60, with higher values indicating worse outcome.

    Time frame: Week 8, 9, 10, 11, 12, and 13

  2. Mean Change From End of Phase A (Week 8 Visit) in MADRS Total Score for Every Study Week Visit in Phase B Other Than Week 14 Visit for the Efficacy Sample Per Final Protocol

    The MADRS was utilized as the primary efficacy assessment of a participant's level of depression. The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place. The MADRS Total Score is the sum of ratings for all 10 items. The possible total scores are from 0 to 60, with higher values indicating worse outcome.

    Time frame: Week 8, 9, 10, 11, 12, and 13

  3. Mean Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Sheehan Disability Scale (SDS) Mean Scores for the Efficacy Sample Set

    The SDS was a self-rated instrument used to measure the effect of the participants symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores ranged from 0 through 10. The number most representative of how much each area was disrupted by symptoms was marked along the line from 0= not at all to 10= extremely. For the work/school item, no response was to be entered if the participant did not work or go to school for reasons unrelated to the disorder and a response therefore not being applicable. The Mean SDS score were calculated over the three item scores. All three item scores were needed to be available with the exception of the work/school item score when this item was not applicable.

    Time frame: Week 11 and Week 14

  4. Mean Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in SDS Mean Scores for the Efficacy Sample Per Final Protocol

    The SDS was a self-rated instrument used to measure the effect of the participants symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores ranged from 0 through 10. The number most representative of how much each area was disrupted by symptoms was marked along the line from 0= not at all, to 10= extremely. For the work/school item, no response was to be entered if the participant did not work or go to school for reasons unrelated to the disorder and a response therefore not being applicable. The Mean SDS score were calculated over the three item scores. All three item scores were needed to be available with the exception of the work/school item score when this item was not applicable.

    Time frame: Week 11 and Week 14

  5. Change From Baseline (End of Phase A [Week 8]) in SDS Item Scores for the Efficacy Sample Set

    The SDS is a self-rated instrument used to measure the effect of the patient's symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores range from 0 through 10. The number most representative of how much each area was disrupted by symptoms is marked along the line from 0 = not at all, to 10 = extremely. For the work/school item, no response was to be entered if the patient did not work or go to school for reasons unrelated to the disorder and a response therefore not being applicable. The Mean SDS Score will be calculated over the three item scores. All three item scores need to be available with the exception of the work/school item score when this item is not applicable.

    Time frame: Week 11 and Week 14

  6. Change From Baseline (End of Phase A [Week 8]) in SDS Item Scores for the Efficacy Sample Set Per Final Protocol

    The SDS is a self-rated instrument used to measure the effect of the patient's symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores range from 0 through 10. The number most representative of how much each area was disrupted by symptoms is marked along the line from 0 = not at all, to 10 = extremely. For the work/school item, no response was to be entered if the patient did not work or go to school for reasons unrelated to the disorder and a response therefore not being applicable. The Mean SDS Score will be calculated over the three item scores. All three item scores need to be available with the exception of the work/school item score when this item is not applicable.

    Time frame: Week 11 and Week 14

  7. Mean Change From End of Phase A (Week 8 Visit) to Phase B by Study Week in Clinical Global Impression Severity of Illness (CGI-S) for the Efficacy Sample Set

    The severity of illness for each participant was rated using the CGI-S. To perform this assessment, the study physician had to answer the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

    Time frame: Weeks 8, 9, 10, 11, 12,13 and 14

  8. Mean Change From End of Phase A (Week 8 Visit) to Phase B by Study Week in Clinical CGI-S for the Efficacy Sample Per Final Protocol

    The severity of illness for each participant was rated using the CGI-S. To perform this assessment, the study physician had to answer the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

    Time frame: Weeks 8, 9, 10, 11, 12, 13, and 14

  9. Mean Change From End of Phase A (Week 8 Visit) for Every Study Week Visit in Phase B in Inventory of Depressive Symptomatology (Self-Report) IDS-SR Total Score for the Efficacy Sample Set

    IDS-SR was a 30-item self-report measured to assess core diagnostic depressive symptoms and atypical and melancholic symptom features of major depressive disorders. The IDS-SR consists of 30 items, all rated on a 0 to 3 scale with 0 being the "best" rating and 3 being the "worst" rating. Besides item 9, two sub-items 9A and 9B exist, with possible scores of 1, 2 or 3 for item 9A, and 0 or 1 for item 9B. The scores for these two sub-items were not included in the calculation of the total score. The IDS-SR Total Score was the sum of ratings of 28 item scores. The possible IDSSR Total Score ranged from 0 to 84. The IDS-SR Total Score was un-evaluable if less than 23 of the 28 items were recorded. If the number of items recorded was at least 23 and at most 27, the IDS-SR Total Score was the mean of the recorded items multiplied by 28, and was then rounded off to the first decimal place.

    Time frame: Weeks 8, 9, 10, 11, 12, 13, and 14

  10. Mean Change From End of Phase A (Week 8 Visit) for Every Study Week Visit in Phase B in IDS-SR Total Score for the Efficacy Sample Per Final Protocol

    The IDS-SR was a 30-item self-report measured to assess core diagnostic depressive symptoms as well as atypical and melancholic symptom features of major depressive disorders. The IDS-SR consists of 30 items, all rated on a 0 to 3 scale with 0 being the "best" rating and 3 being the "worst" rating. Besides item 9, two sub-items 9A and 9B exist, with possible scores of 1, 2 or 3 for item 9A, and 0 or 1 for item 9B. The scores for these two sub-items were not included in the calculation of the total score. The IDSSR Total Score was the sum of ratings of 28 item scores. The possible IDSSR Total Score ranged from 0 to 84. The IDS-SR Total Score was un-evaluable if less than 23 of the 28 items were recorded. If the number of items recorded was at least 23 and at most 27, the IDS-SR Total Score was the mean of the recorded items multiplied by 28, and was then rounded off to the first decimal place.

    Time frame: Weeks 8, 9, 10, 11, 12, 13, and 14

  11. Mean Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) Hamilton Depression Scale 17 Item Version (HAM)-D17 Total Score for the Efficacy Sample Set

    The HAM-D17 was utilized as a secondary assessment of a participants level of depression. The HAM-D (17-Item) consisted of 17 items. Eight items were rated on a 0 to 2 scale (items 4, 5, 6, 12, 13, 14, 16 and 17), while nine items (items 1, 2, 3, 7, 8, 9, 10, 11, and 15) were rated on a 0 to 4 scale (twice the weight of the other items). For all of these items, 0 was the "best" rating and the highest score (2 or 4) was the "worst" rating. The possible total scores were from 0 to 52, with higher scores indicating more severe depression.

    Time frame: Baseline and Week 14

  12. Mean Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in HAM-D17 Total Score for the Efficacy Sample Set Per Final Protocol

    The HAM-D17 was utilized as a secondary assessment of a participants level of depression. The HAM-D (17-Item) consisted of 17 items. Eight items were rated on a 0 to 2 scale (items 4, 5, 6, 12, 13, 14, 16 and 17), while nine items (items 1, 2, 3, 7, 8, 9, 10, 11, and 15) were rated on a 0 to 4 scale (twice the weight of the other items). For all of these items, 0 was the "best" rating and the highest score (2 or 4) was the "worst" rating. The possible total scores were from 0 to 52, with higher score indicating more severe depression.

    Time frame: Baseline and Week 14

  13. Mean Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Hamilton Anxiety Rating Scale (HAM-A) Total Score for the Efficacy Sample Set

    The HAM-A is utilized for the evaluation of anxiety symptoms. The HAM-A consists of 14 items. Each item is rated on a 0 to 4 scale. For all of these items, 0 is the "best" rating and 4 is the "worst" rating. If no item scores are missing, then the HAM-A total score is the sum of all 14 item scores. The possible total scores are from 0 to 56, with higher scores indicating worse anxiety symptoms.

    Time frame: Baseline and Week 14

  14. Mean Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in HAM-A Total for the Efficacy Sample Per Final Protocol

    The HAM-A is utilized for the evaluation of anxiety symptoms. The HAM-A consists of 14 items. Each item is rated on a 0 to 4 scale. For all of these items, 0 is the "best" rating and 4 is the "worst" rating. If no item scores are missing, then the HAM-A total score is the sum of all 14 item scores. The possible total scores are from 0 to 56, with higher score indicating worse anxiety symptoms.

    Time frame: Baseline and Week 14

  15. Mean CGI-I Score at Each Trial Week Visit in Phase B for the Efficacy Sample Set

    The efficacy of study medication was rated for each participant using the CGI-I. The study physician would rate the participant's total improvement whether or not it is due entirely to drug treatment. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.

    Time frame: Week 8 to Week 14

  16. Mean CGI-I Score at Each Trial Week Visit in Phase B for the Efficacy Sample Per Final Protocol

    The efficacy of study medication was rated for each participant using the CGI-I. The study physician would rate the participant's total improvement whether or not it is due entirely to drug treatment. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.

    Time frame: Weeks 8, 9, 10, 11, 12, 13, and 14

  17. Percentage of Participants With a MADRS Response During Phase B Relative to the End of Phase A (Week 8 Visit) for the Efficacy Sample Set

    MADRS response was defined as \>=50 percent reduction in MADRS Total Score from end of Phase A (Week 8). The MADRS was utilized as an efficacy assessment of a participant's level of depression. The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place. The MADRS Total Score is the sum of ratings for all 10 items. The possible total scores are from 0 to 60, with higher values indicating worse outcome.

    Time frame: Weeks 8, 9, 10, 11, 12, 13, and 14

  18. Percentage of Participants With a MADRS Response During Phase B Relative to the End of Phase A (Week 8 Visit) for the Efficacy Sample Per Final Protocol

    MADRS response was defined as \>=50 percent reduction in MADRS Total Score from end of Phase A (Week 8). The MADRS was utilized as an efficacy assessment of a participant's level of depression. The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place. The MADRS Total Score is the sum of ratings for all 10 items. The possible total scores are from 0 to 60, with higher values indicating worse outcome.

    Time frame: Weeks 8, 9, 10, 11, 12, 13, and 14

  19. Percentage of Participants With a MADRS Remission During Phase B Relative to the End of Phase A (Week 8) for the Efficacy Sample Set

    MADRS remission was defined as a \< or equal to 10 and \> or equal to 50% reduction in MADRS Total Score from end of Phase A (Week 8). The MADRS was utilized as an efficacy assessment of a participant's level of depression. The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place. The MADRS Total Score is the sum of ratings for all 10 items. The possible total scores are from 0 to 60, with higher values indicating worse outcome.

    Time frame: Weeks 8, 9, 10, 11, 12, 13 and 14

  20. Percentage of Participants With a MADRS Remission During Phase B Relative to the End of Phase A (Week 8) for the Efficacy Sample Per Final Protocol

    MADRS remission was defined as a \< or equal to 10 and \> or equal to 50% reduction in MADRS Total Score from end of Phase A (Week 8). The MADRS was utilized as an efficacy assessment of a participant's level of depression. The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place. The MADRS Total Score is the sum of ratings for all 10 items. The possible total scores are from 0 to 60, with higher values indicating worse outcome.

    Time frame: Weeks 8, 9, 10, 11, 12, 13 and 14

  21. Percentage of Participants With a CGI-I Response During Phase B Relative to the End of Phase A (Week 8 Visit) for the Efficacy Sample Set

    A CGI-I response was defined as a CGI-I score of 1 (very much improved) or 2 (much improved).

    Time frame: Weeks 8, 9, 10, 11, 12, 13 and 14

  22. Percentage of Participants With a CGI-I Response During Phase B Relative to the End of Phase A (Week 8 Visit) for the Efficacy Sample Per Final Protocol

    A CGI-I response was defined as a CGI-I score of 1 (very much improved) or 2 (much improved).

    Time frame: Weeks, 8, 9, 10, 11, 12, 13, and 14

08

Results

Posted Jan 1, 2016

Participant flow

The study was conducted in 1539 participants at 92 trial sites in 7 countries. United States, Germany, Ukraine, Russia, Hungary, Canada, and Romania.

Phase A (8 Weeks)
Participant flow — Phase A (8 Weeks)
MilestoneSingle-blind Placebo + ADTBrexpiprazole (1mg) + ADTBrexpiprazole (3mg) + ADTDouble-blind Placebo + ADTPhase A+ Placebo + ADT
Started15320000
Completed12770000
Not completed2550000
Withdrew: Lost to follow-up270000
Withdrew: Adverse event600000
Withdrew: Met withdrawal criteria450000
Withdrew: Physician decision100000
Withdrew: Withdrawal by subject740000
Withdrew: Protocol deviation390000
Phase B (6 Weeks)
Participant flow — Phase B (6 Weeks)
MilestoneSingle-blind Placebo + ADTBrexpiprazole (1mg) + ADTBrexpiprazole (3mg) + ADTDouble-blind Placebo + ADTPhase A+ Placebo + ADT
Started02262302210
Completed02162102080
Not completed01020130
Withdrew: Lost to follow-up01100
Withdrew: Adverse event03930
Withdrew: Met withdrawal criteria00210
Withdrew: Physician decision00010
Withdrew: Withdrawal by subject04470
Withdrew: Protocol deviation01410
Withdrew: Lack of efficacy01000
Phase A+
Participant flow — Phase A+
MilestoneSingle-blind Placebo + ADTBrexpiprazole (1mg) + ADTBrexpiprazole (3mg) + ADTDouble-blind Placebo + ADTPhase A+ Placebo + ADT
Started0000600
Completed0000575
Not completed000025
Withdrew: Lost to follow-up00002
Withdrew: Adverse event00002
Withdrew: Met withdrawal criteria00007
Withdrew: Physician decision00003
Withdrew: Withdrawal by subject00008
Withdrew: Protocol deviation00003

Outcome measures

PrimaryMean Change From the End of Phase A (Week 8 Visit) to Phase B (Week 14 Visit) in the Montgomery-Asberg Depression Rating Scale for the Efficacy Sample Set

The MADRS was utilized as the primary efficacy assessment of a participant's level of depression. The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place. The MADRS Total Score is the sum of ratings for all 10 items. The possible total scores are from 0 to 60, with higher values indicating worse outcome.

Time frame:
Baseline and Week 14
Reported as:
Least squares mean · Units on a scale
Mean Change From the End of Phase A (Week 8 Visit) to Phase B (Week 14 Visit) in the Montgomery-Asberg Depression Rating Scale for the Efficacy Sample Set
Units on a scaleBrexpiprazole (1mg) + ADTBrexpiprazole (3mg) + ADTPlacebo + ADT
Mean Change From the End of Phase A (Week 8 Visit) to Phase B (Week 14 Visit) in the Montgomery-Asberg Depression Rating Scale for the Efficacy Sample Set-7.65 ± 0.5-7.98 ± 0.51-6.45 ± 0.51
Statistical analysis
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0925 · Mean difference (final values): -1.19 · 95% CI -2.58 to 0.2MMRM method was used with trial site; treatment group-visit; Baseline-visit interaction as an unstructured covariate.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0327 · Mean difference (final values): -1.52 · 95% CI -2.92 to -0.13MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
PrimaryMean Change in MADRS Total Score From Baseline End of Week 8 to Week 14 for the Efficacy Sample Per Final Protocol

The MADRS was utilized as the primary efficacy assessment of a participant's level of depression. The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place. The MADRS Total Score is the sum of ratings for all 10 items. The possible total scores are from 0 to 60, with higher values indicating worse outcome.

Time frame:
Baseline and Week 14
Reported as:
Least squares mean · Units on a scale
Mean Change in MADRS Total Score From Baseline End of Week 8 to Week 14 for the Efficacy Sample Per Final Protocol
Units on a scaleBrexpiprazole (1mg) + ADTBrexpiprazole (3mg) + ADTPlacebo + ADT
Mean Change in MADRS Total Score From Baseline End of Week 8 to Week 14 for the Efficacy Sample Per Final Protocol-7.64 ± 0.52-8.29 ± 0.536.33 ± 0.53
Statistical analysis
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0737 · Mean difference (final values): -1.30 · 95% CI -2.73 to 0.13MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0079 · Mean difference (final values): -1.95 · 95% CI -3.39 to -0.51MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
SecondaryMean Change From End of Phase A (Week 8 Visit) in MADRS Total Score for Every Study Week Visit in Phase B Other Than Week 14 Visit for the Efficacy Sample Set

The MADRS was utilized as the primary efficacy assessment of a participant's level of depression. The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place. The MADRS Total Score is the sum of ratings for all 10 items. The possible total scores are from 0 to 60, with higher values indicating worse outcome.

Time frame:
Week 8, 9, 10, 11, 12, and 13
Reported as:
Least squares mean · Units on a scale
Mean Change From End of Phase A (Week 8 Visit) in MADRS Total Score for Every Study Week Visit in Phase B Other Than Week 14 Visit for the Efficacy Sample Set
Units on a scaleBrexpiprazole (1mg) + ADTBrexpiprazole (3mg) + ADTPlacebo + ADT
Week 9-3.25 ± 0.3-2.53 ± 0.3-2.19 ± 0.31
Week 10-5.34 ± 0.38-4.8 ± 0.38-3.91 ± 0.39
Week 11-6.25 ± 0.41-5.56 ± 0.41-4.85 ± 0.41
Week 12-7.08 ± 0.43-6.8 ± 0.44-5.52 ± 0.44
Week 13-7.55 ± 0.46-7.73 ± 0.46-6.04 ± 0.47
Statistical analysis
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0096 · Mean difference (final values): -1.06 · 95% CI -1.86 to -0.26MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.4137 · Mean difference (final values): -0.33 · 95% CI -1.14 to 0.47MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0065 · Mean difference (final values): -1.44 · 95% CI -2.47 to -0.4MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0914 · Mean difference (final values): -0.89 · 95% CI -1.93 to 0.14MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0139 · Mean difference (final values): -1.39 · 95% CI -2.5 to -0.28MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.2097 · Mean difference (final values): -0.71 · 95% CI -1.82 to 0.4MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0099 · Mean difference (final values): -1.56 · 95% CI -2.75 to -0.38MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.034 · Mean difference (final values): -1.29 · 95% CI -2.48 to -0.1MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0177 · Mean difference (final values): -1.53 · 95% CI -2.8 to -0.27MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0085 · Mean difference (final values): -1.71 · 95% CI -2.98 to -0.44MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
SecondaryMean Change From End of Phase A (Week 8 Visit) in MADRS Total Score for Every Study Week Visit in Phase B Other Than Week 14 Visit for the Efficacy Sample Per Final Protocol

The MADRS was utilized as the primary efficacy assessment of a participant's level of depression. The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place. The MADRS Total Score is the sum of ratings for all 10 items. The possible total scores are from 0 to 60, with higher values indicating worse outcome.

Time frame:
Week 8, 9, 10, 11, 12, and 13
Reported as:
Least squares mean · Units on a scale
Mean Change From End of Phase A (Week 8 Visit) in MADRS Total Score for Every Study Week Visit in Phase B Other Than Week 14 Visit for the Efficacy Sample Per Final Protocol
Units on a scaleBrexpiprazole (1mg) + ADTBrexpiprazole (3mg) + ADTPlacebo + ADT
Week 9-3.09 ± 0.31-2.6 ± 0.31-2.18 ± 0.32
Week 10-5.12 ± 0.39-4.92 ± 0.39-3.95 ± 0.4
Week 11-6.22 ± 0.42-5.76 ± 0.43-4.86 ± 0.43
Week 12-7.09 ± 0.45-7.11 ± 0.45-5.48 ± 0.46
Week 13-7.56 ± 0.47-8.05 ± 0.48-5.93 ± 0.49
Statistical analysis
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0286 · Mean difference (final values): -0.92 · 95% CI -1.74 to -0.1MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.3173 · Mean difference (final values): -0.42 · 95% CI -1.24 to 0.4MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0313 · Mean difference (final values): -1.17 · 95% CI -2.23 to -0.11MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0732 · Mean difference (final values): -0.97 · 95% CI -2.04 to 0.09MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0206 · Mean difference (final values): -1.36 · 95% CI -2.51 to -0.21MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.1233 · Mean difference (final values): -0.91 · 95% CI -2.06 to 0.25MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0097 · Mean difference (final values): -1.61 · 95% CI -2.84 to -0.39MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0092 · Mean difference (final values): -1.63 · 95% CI -2.86 to -0.41MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0139 · Mean difference (final values): -1.63 · 95% CI -2.94 to -0.33MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0015 · Mean difference (final values): -2.12 · 95% CI -3.42 to -0.81MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
SecondaryMean Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Sheehan Disability Scale (SDS) Mean Scores for the Efficacy Sample Set

The SDS was a self-rated instrument used to measure the effect of the participants symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores ranged from 0 through 10. The number most representative of how much each area was disrupted by symptoms was marked along the line from 0= not at all to 10= extremely. For the work/school item, no response was to be entered if the participant did not work or go to school for reasons unrelated to the disorder and a response therefore not being applicable. The Mean SDS score were calculated over the three item scores. All three item scores were needed to be available with the exception of the work/school item score when this item was not applicable.

Time frame:
Week 11 and Week 14
Reported as:
Least squares mean · Units on a scale
Mean Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Sheehan Disability Scale (SDS) Mean Scores for the Efficacy Sample Set
Units on a scaleBrexpiprazole (1mg) + ADTBrexpiprazole (3mg) + ADTPlacebo + ADT
Week 11-1.13 ± 0.13-0.67 ± 0.13-0.58 ± 0.11
Week 14-1.33 ± 0.14-1.21 ± 0.13-0.84 ± 0.13
Statistical analysis
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0008 (MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.) · Mean difference (final values): -0.55 · 95% CI -0.87 to -0.23
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.5792 (MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.) · Mean difference (final values): -0.09 · 95% CI -0.41 to 0.23
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0091 · Mean difference (final values): -0.49 · 95% CI -0.87 to -0.12MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0474 · Mean difference (final values): -0.37 · 95% CI -0.73 to 0MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
SecondaryMean Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in SDS Mean Scores for the Efficacy Sample Per Final Protocol

The SDS was a self-rated instrument used to measure the effect of the participants symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores ranged from 0 through 10. The number most representative of how much each area was disrupted by symptoms was marked along the line from 0= not at all, to 10= extremely. For the work/school item, no response was to be entered if the participant did not work or go to school for reasons unrelated to the disorder and a response therefore not being applicable. The Mean SDS score were calculated over the three item scores. All three item scores were needed to be available with the exception of the work/school item score when this item was not applicable.

Time frame:
Week 11 and Week 14
Reported as:
Least squares mean · Units on a scale
Mean Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in SDS Mean Scores for the Efficacy Sample Per Final Protocol
Units on a scaleBrexpiprazole (1mg) + ADTBrexpiprazole (3mg) + ADTPlacebo + ADT
Week 11-1.11 ± 0.13-0.74 ± 0.13-0.53 ± 0.14
Week 14-1.27 ± 0.15-1.26 ± 0.15-0.78 ± 0.15
Statistical analysis
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0015 (MMRM method was used with trial site; treatment group-visit; Baseline-visit interaction as an unstructured covariate.) · Mean difference (final values): -0.58 · 95% CI -0.94 to -0.22
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.2627 (MMRM method was used with trial site; treatment group-visit; Baseline-visit interaction as an unstructured covariate) · Mean difference (final values): -0.21 · 95% CI -0.56 to 0.15
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0158 · Mean difference (final values): -0.49 · 95% CI -0.89 to -0.09MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0191 · Mean difference (final values): -0.48 · 95% CI -0.88 to -0.08MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
SecondaryChange From Baseline (End of Phase A [Week 8]) in SDS Item Scores for the Efficacy Sample Set

The SDS is a self-rated instrument used to measure the effect of the patient's symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores range from 0 through 10. The number most representative of how much each area was disrupted by symptoms is marked along the line from 0 = not at all, to 10 = extremely. For the work/school item, no response was to be entered if the patient did not work or go to school for reasons unrelated to the disorder and a response therefore not being applicable. The Mean SDS Score will be calculated over the three item scores. All three item scores need to be available with the exception of the work/school item score when this item is not applicable.

Time frame:
Week 11 and Week 14
Reported as:
Least squares mean · Units on a scale
Change From Baseline (End of Phase A [Week 8]) in SDS Item Scores for the Efficacy Sample Set
Units on a scaleBrexpiprazole (1mg) + ADTBrexpiprazole (3mg) + ADTPlacebo + ADT
Work/school: Week 11-1.00 ± 0.16-0.18 ± 0.18-0.55 ± 0.15
Work/school: Week 14-1.16 ± 0.17-0.91 ± 0.18-0.73 ± 0.17
Social life: Week 11-1.13 ± 0.14-0.76 ± 0.14-0.72 ± 0.14
Social life: Week 14-1.39 ± 0.15-1.31 ± 0.15-0.91 ± 0.15
Family life: Week 11-1.14 ± 0.14-0.74 ± 0.14-0.51 ± 0.12
Family life: Week 14-1.35 ± 0.15-1.28 ± 0.16-0.80 ± 0.15
Statistical analysis
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0377 · Mean difference (final values): -0.45 · 95% CI -0.88 to -0.03MMRM method was used with trial site; treatment group-visit; Baseline-visit interaction as an unstructured covariate.
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0741 (MMRM method was used with trial site; treatment group-visit; Baseline-visit interaction as an unstructured covariate.) · Mean difference (final values): -0.43 · 95% CI -0.91 to 0.04-0.43
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0966 (MMRM method was used with trial site; treatment group-visit; Baseline-visit interaction as an unstructured covariate.) · Mean difference (final values): 0.37 · 95% CI -0.07 to 0.81
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.4774 · Mean difference (final values): -0.18 · 95% CI -0.66 to 0.31
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0263 (MMRM method was used with trial site; treatment group-visit; Baseline-visit interaction as an unstructured covariate.) · Mean difference (final values): -0.41 · 95% CI -0.76 to -0.05
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0214 · Mean difference (final values): -0.48 · 95% CI -0.89 to -0.07
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.8281 (MMRM method was used with trial site; treatment group-visit; Baseline-visit interaction as an unstructured covariate.) · Mean difference (final values): -0.04 · 95% CI -0.40 to 0.32
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0540 · Mean difference (net): -0.40 · 95% CI -0.80 to 0.01
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0008 (MMRM method was used with trial site; treatment group-visit; Baseline-visit interaction as an unstructured covariate.) · Mean difference (net): -0.63 · 95% CI -0.99 to -0.26
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0093 · Mean difference (final values): -0.55 · 95% CI -0.97 to -0.14
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.2182 · Mean difference (final values): -0.23 · 95% CI -0.59 to 0.14
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0256 (MMRM method was used with trial site; treatment group-visit; Baseline-visit interaction as an unstructured covariate.) · Mean difference (final values): -0.48 · 95% CI -0.90 to -0.06
SecondaryChange From Baseline (End of Phase A [Week 8]) in SDS Item Scores for the Efficacy Sample Set Per Final Protocol

The SDS is a self-rated instrument used to measure the effect of the patient's symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores range from 0 through 10. The number most representative of how much each area was disrupted by symptoms is marked along the line from 0 = not at all, to 10 = extremely. For the work/school item, no response was to be entered if the patient did not work or go to school for reasons unrelated to the disorder and a response therefore not being applicable. The Mean SDS Score will be calculated over the three item scores. All three item scores need to be available with the exception of the work/school item score when this item is not applicable.

Time frame:
Week 11 and Week 14
Reported as:
Least squares mean · Units on a scale
Change From Baseline (End of Phase A [Week 8]) in SDS Item Scores for the Efficacy Sample Set Per Final Protocol
Units on a scaleBrexpiprazole (1mg) + ADTBrexpiprazole (3mg) + ADTPlacebo + ADT
Work/school: Week 11-1.01 ± 0.18-0.20 ± 0.20-0.48 ± 0.19
Work/school: Week 14-1.11 ± 0.20-0.93 ± 0.21-0.65 ± 0.20
Social life: Week 11-1.11 ± 0.15-0.82 ± 0.15-0.68 ± 0.15
Social life: Week 14-1.34 ± 0.16-1.37 ± 0.16-0.88 ± 0.17
Family life: Week 11-1.17 ± 0.14-0.89 ± 0.15-0.54 ± 0.15
Family life: Week 14-1.32 ± 0.16-1.39 ± 0.16-0.81 ± 0.16
Statistical analysis
  • Brexpiprazole (1mg) + ADT · Mixed Models Analysis · p = 0.0341 (MMRM method was used with trial site; treatment group-visit; Baseline-visit interaction as an unstructured covariate.) · Mean difference (final values): -0.53 · 95% CI -1.01 to -0.04
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0816 (MMRM method was used with trial site; treatment group-visit; Baseline-visit interaction as an unstructured covariate.) · Mean difference (final values): -0.46 · 95% CI -0.99 to 0.06
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.2561 (MMRM method was used with trial site; treatment group-visit; Baseline-visit interaction as an unstructured covariate.) · Mean difference (final values): 0.29 · 95% CI -0.21 to 0.78
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.2952 (MMRM method was used with trial site; treatment group-visit; Baseline-visit interaction as an unstructured covariate.) · Mean difference (final values): -0.29 · 95% CI -0.82 to 0.25
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0331 (MMRM method was used with trial site; treatment group-visit; Baseline-visit interaction as an unstructured covariate.) · Mean difference (final values): -0.43 · 95% CI -0.82 to -0.03
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0352 · Mean difference (final values): -0.47 · 95% CI -0.90 to -0.03
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.4860 (MMRM method was used with trial site; treatment group-visit; Baseline-visit interaction as an unstructured covariate.) · Mean difference (final values): -0.14 · 95% CI -0.54 to 0.25
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0282 (MMRM method was used with trial site; treatment group-visit; Baseline-visit interaction as an unstructured covariate.) · Mean difference (final values): -0.49 · 95% CI -0.93 to -0.05
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0016 (MMRM method was used with trial site; treatment group-visit; Baseline-visit interaction as an unstructured covariate.) · Mean difference (final values): -0.62 · 95% CI -1.01 to -0.24
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0186 · Mean difference (final values): -0.51 · 95% CI -0.94 to -0.09
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0824 (MMRM method was used with trial site; treatment group-visit; Baseline-visit interaction as an unstructured covariate.) · Mean difference (final values): -0.35 · 95% CI -0.73 to 0.04
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0077 (MMRM method was used with trial site; treatment group-visit; Baseline-visit interaction as an unstructured covariate.) · Mean difference (final values): -0.59 · 95% CI -1.02 to -0.16
SecondaryMean Change From End of Phase A (Week 8 Visit) to Phase B by Study Week in Clinical Global Impression Severity of Illness (CGI-S) for the Efficacy Sample Set

The severity of illness for each participant was rated using the CGI-S. To perform this assessment, the study physician had to answer the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

Time frame:
Weeks 8, 9, 10, 11, 12,13 and 14
Reported as:
Least squares mean · Units on a scale
Mean Change From End of Phase A (Week 8 Visit) to Phase B by Study Week in Clinical Global Impression Severity of Illness (CGI-S) for the Efficacy Sample Set
Units on a scaleBrexpiprazole (1mg) + ADTBrexpiprazole (3mg) + ADTPlacebo + ADT
Week 9-0.25 ± 0.03-0.22 ± 0.03-0.16 ± 0.03
Week 10-0.52 ± 0.05-0.46 ± 0.05-0.31 ± 0.05
Week 11-0.64 ± 0.05-0.51 ± 0.05-0.44 ± 0.05
Week 12-0.73 ± 0.05-0.72 ± 0.05-0.59 ± 0.05
Week 13-0.78 ± 0.06-0.77 ± 0.06-0.66 ± 0.06
Week 14-0.86 ± 0.06-0.9 ± 0.06-0.75 ± 0.06
Statistical analysis
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0436 · Mean difference (final values): -0.09 · 95% CI -0.18 to 0MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = -0.06 · Mean difference (final values): -0.06 · 95% CI -0.15 to 0.03MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0012 · Mean difference (final values): -0.21 · 95% CI -0.34 to -0.08MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0266 · Mean difference (final values): -0.14 · 95% CI -0.27 to -0.02MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0034 · Mean difference (final values): -0.2 · 95% CI -0.33 to -0.07MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.3053 · Mean difference (final values): -0.07 · 95% CI -0.2 to 0.06MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0541 · Mean difference (final values): -0.15 · 95% CI -0.29 to 0MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0912 · Mean difference (final values): -0.13 · 95% CI -0.28 to 0.02MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.1553 · Mean difference (final values): -0.12 · 95% CI -0.28 to 0.04MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.1855 · Mean difference (final values): -0.11 · 95% CI -0.27 to 0.05MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.2015 · Mean difference (final values): -0.11 · 95% CI -0.28 to 0.06MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0852 · Mean difference (final values): -0.15 · 95% CI -0.32 to 0.02MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
SecondaryMean Change From End of Phase A (Week 8 Visit) to Phase B by Study Week in Clinical CGI-S for the Efficacy Sample Per Final Protocol

The severity of illness for each participant was rated using the CGI-S. To perform this assessment, the study physician had to answer the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

Time frame:
Weeks 8, 9, 10, 11, 12, 13, and 14
Reported as:
Least squares mean · Units on a scale
Mean Change From End of Phase A (Week 8 Visit) to Phase B by Study Week in Clinical CGI-S for the Efficacy Sample Per Final Protocol
Units on a scaleBrexpiprazole (1mg) + ADTBrexpiprazole (3mg) + ADTPlacebo + ADT
Week 9-0.24 ± 0.03-0.23 ± 0.03-0.16 ± 0.03
Week 10-0.5 ± 0.05-0.47 ± 0.05-0.33 ± 0.05
Week 11-0.64 ± 0.05-0.53 ± 0.05-0.45 ± 0.05
Week 12-0.73 ± 0.06-0.74 ± 0.06-0.58 ± 0.06
Week 13-0.77 ± 0.06-0.8 ± 0.06-0.64 ± 0.06
Week 14-0.87 ± 0.06-0.92 ± 0.06-0.72 ± 0.06
Statistical analysis
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0817 · Median difference (final values): -0.08 · 95% CI -0.17 to 0.01MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.1406 · Mean difference (final values): -0.07 · 95% CI -0.16 to 0.02MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.011 · Mean difference (final values): -0.17 · 95% CI -0.29 to -0.04MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0287 · Mean difference (final values): -0.14 · 95% CI -0.27 to -0.02MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0071 · Mean difference (final values): -0.19 · 95% CI -0.32 to -0.05MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.2503 · Mean difference (final values): -0.08 · 95% CI -0.22 to -0.06MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0539 · Mean difference (final values): -0.15 · 95% CI -0.3 to 0MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0398 · Mean difference (final values): -0.16 · 95% CI -0.31 to -0.01MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.1168 · Mean difference (final values): -0.13 · 95% CI -0.3 to 0.03MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0621 · Mean difference (final values): -0.16 · 95% CI -0.32 to 0.01MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.089 · Mean difference (final values): -0.15 · 95% CI -0.32 to 0.02MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0213 · Mean difference (final values): -0.2 · 95% CI -0.38 to -0.03MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
SecondaryMean Change From End of Phase A (Week 8 Visit) for Every Study Week Visit in Phase B in Inventory of Depressive Symptomatology (Self-Report) IDS-SR Total Score for the Efficacy Sample Set

IDS-SR was a 30-item self-report measured to assess core diagnostic depressive symptoms and atypical and melancholic symptom features of major depressive disorders. The IDS-SR consists of 30 items, all rated on a 0 to 3 scale with 0 being the "best" rating and 3 being the "worst" rating. Besides item 9, two sub-items 9A and 9B exist, with possible scores of 1, 2 or 3 for item 9A, and 0 or 1 for item 9B. The scores for these two sub-items were not included in the calculation of the total score. The IDS-SR Total Score was the sum of ratings of 28 item scores. The possible IDSSR Total Score ranged from 0 to 84. The IDS-SR Total Score was un-evaluable if less than 23 of the 28 items were recorded. If the number of items recorded was at least 23 and at most 27, the IDS-SR Total Score was the mean of the recorded items multiplied by 28, and was then rounded off to the first decimal place.

Time frame:
Weeks 8, 9, 10, 11, 12, 13, and 14
Reported as:
Least squares mean · Units on a scale
Mean Change From End of Phase A (Week 8 Visit) for Every Study Week Visit in Phase B in Inventory of Depressive Symptomatology (Self-Report) IDS-SR Total Score for the Efficacy Sample Set
Units on a scaleBrexpiprazole (1mg) + ADTBrexpiprazole (3mg) + ADTPlacebo + ADT
Week 9-3.58 ± 0.41-2.68 ± 0.42-2.31 ± 0.42
Week 10-4.97 ± 0.49-4.00 ± 0.5-3.11 ± 0.5
Week 11-5.83 ± 0.56-4.15 ± 0.56-3.74 ± 0.57
Week 12-6.33 ± 0.59-5.77 ± 0.59-4.43 ± 0.6
Week 13-6.96 ± 0.63-6.62 ± 0.63-5.66 ± 0.64
Week 14-7.02 ± 0.66-6.94 ± 0.66-5.42 ± 0.67
Statistical analysis
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0228 · Mean difference (final values): -1.28 · 95% CI -2.37 to -0.18MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.5081 · Mean difference (final values): -0.37 · 95% CI -1.47 to 0.73MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0064 · Mean difference (final values): -1.86 · 95% CI -3.2 to -0.53MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.1898 · Mean difference (final values): -0.89 · 95% CI -2.23 to 0.44MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0074 · Mean difference (final values): -2.09 · 95% CI -3.62 to -0.56MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.5935 · Mean difference (final values): -0.42 · 95% CI -1.95 to 1.11MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0211 · Mean difference (final values): -1.9 · 95% CI -3.52 to -0.29MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.1031 · Mean difference (final values): -1.34 · 95% CI -2.96 to 0.27MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.1366 · Mean difference (final values): 0.1366 · 95% CI -3.02 to 0.41MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.2709 · Mean difference (final values): -0.96 · 95% CI -2.68 to 0.75MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0812 · Mean difference (final values): -1.6 · 95% CI -3.4 to 0.2MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.1001 · Mean difference (final values): -1.52 · 95% CI -3.33 to 0.29MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
SecondaryMean Change From End of Phase A (Week 8 Visit) for Every Study Week Visit in Phase B in IDS-SR Total Score for the Efficacy Sample Per Final Protocol

The IDS-SR was a 30-item self-report measured to assess core diagnostic depressive symptoms as well as atypical and melancholic symptom features of major depressive disorders. The IDS-SR consists of 30 items, all rated on a 0 to 3 scale with 0 being the "best" rating and 3 being the "worst" rating. Besides item 9, two sub-items 9A and 9B exist, with possible scores of 1, 2 or 3 for item 9A, and 0 or 1 for item 9B. The scores for these two sub-items were not included in the calculation of the total score. The IDSSR Total Score was the sum of ratings of 28 item scores. The possible IDSSR Total Score ranged from 0 to 84. The IDS-SR Total Score was un-evaluable if less than 23 of the 28 items were recorded. If the number of items recorded was at least 23 and at most 27, the IDS-SR Total Score was the mean of the recorded items multiplied by 28, and was then rounded off to the first decimal place.

Time frame:
Weeks 8, 9, 10, 11, 12, 13, and 14
Reported as:
Least squares mean · Units on a scale
Mean Change From End of Phase A (Week 8 Visit) for Every Study Week Visit in Phase B in IDS-SR Total Score for the Efficacy Sample Per Final Protocol
Units on a scaleBrexpiprazole (1mg) + ADTBrexpiprazole (3mg) + ADTPlacebo + ADT
Week 9-3.27 ± 0.42-2.65 ± 0.42-2.15 ± 0.43
Week 10-4.7 ± 0.51-4.13 ± 0.51-2.94 ± 0.52
Week 11-5.77 ± 0.57-4.29 ± 0.58-3.46 ± 0.59
Week 12-6.33 ± 0.61-6.05 ± 0.61-4.18 ± 0.63
Week 13-6.88 ± 0.64-6.97 ± 0.64-5.25 ± 0.66
Week 14-6.97 ± 0.67-7.2 ± 0.68-5.07 ± 0.69
Statistical analysis
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0496 · Mean difference (final values): -1.12 · 95% CI -2.24 to 0MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.387 · Mean difference (final values): -0.49 · 95% CI -1.61 to 0.63MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0125 · Mean difference (final values): -1.75 · 95% CI -3.13 to -0.38MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0898 · Mean difference (final values): -1.19 · 95% CI -2.57 to 0.19MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.004 · Mean difference (final values): -2.31 · 95% CI -3.88 to -0.74MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.301 · Mean difference (final values): -0.83 · 95% CI -2.4 to 0.74MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0118 · Mean difference (final values): -2.15 · 95% CI -3.82 to -0.48MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0287 · Mean difference (final values): -1.87 · 95% CI -3.54 to -0.19MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0686 · Mean difference (final values): -1.63 · 95% CI -3.39 to 0.12MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.056 · Mean difference (final values): -1.72 · 95% CI -3.47 to 0.04MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0448 · Mean difference (final values): -1.9 · 95% CI -3.75 to -0.04MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Mixed Models Analysis · p = 0.0251 · Mean difference (final values): -2.13 · 95% CI -3.98 to -0.27MMRM method was used with trial site, treatment group, visit, treatment group-by-visit and Baseline-by-visit interaction as an unstructured covariate.
SecondaryMean Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) Hamilton Depression Scale 17 Item Version (HAM)-D17 Total Score for the Efficacy Sample Set

The HAM-D17 was utilized as a secondary assessment of a participants level of depression. The HAM-D (17-Item) consisted of 17 items. Eight items were rated on a 0 to 2 scale (items 4, 5, 6, 12, 13, 14, 16 and 17), while nine items (items 1, 2, 3, 7, 8, 9, 10, 11, and 15) were rated on a 0 to 4 scale (twice the weight of the other items). For all of these items, 0 was the "best" rating and the highest score (2 or 4) was the "worst" rating. The possible total scores were from 0 to 52, with higher scores indicating more severe depression.

Time frame:
Baseline and Week 14
Reported as:
Least squares mean · Units on a scale
Mean Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) Hamilton Depression Scale 17 Item Version (HAM)-D17 Total Score for the Efficacy Sample Set
Units on a scaleBrexpiprazole (1mg) + ADTBrexpiprazole (3mg) + ADTPlacebo + ADT
Mean Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) Hamilton Depression Scale 17 Item Version (HAM)-D17 Total Score for the Efficacy Sample Set-5.47 ± 0.36-6.14 ± 0.36-4.8 ± 0.37
Statistical analysis
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · ANCOVA · p = 0.1732 · Mean difference (final values): -0.67 · 95% CI -1.63 to 0.29
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · ANCOVA · p = 0.0066 · Mean difference (final values): -1.34 · 95% CI -2.31 to -0.37
SecondaryMean Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in HAM-D17 Total Score for the Efficacy Sample Set Per Final Protocol

The HAM-D17 was utilized as a secondary assessment of a participants level of depression. The HAM-D (17-Item) consisted of 17 items. Eight items were rated on a 0 to 2 scale (items 4, 5, 6, 12, 13, 14, 16 and 17), while nine items (items 1, 2, 3, 7, 8, 9, 10, 11, and 15) were rated on a 0 to 4 scale (twice the weight of the other items). For all of these items, 0 was the "best" rating and the highest score (2 or 4) was the "worst" rating. The possible total scores were from 0 to 52, with higher score indicating more severe depression.

Time frame:
Baseline and Week 14
Reported as:
Least squares mean · Units on a scale
Mean Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in HAM-D17 Total Score for the Efficacy Sample Set Per Final Protocol
Units on a scaleBrexpiprazole (1mg) + ADTBrexpiprazole (3mg) + ADTPlacebo + ADT
Mean Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in HAM-D17 Total Score for the Efficacy Sample Set Per Final Protocol-5.36 ± 0.37-6.26 ± 0.38-4.57 ± 0.39
Statistical analysis
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · ANCOVA · p = 0.1226 · Mean difference (final values): -0.78 · 95% CI -1.78 to 0.21
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · ANCOVA · p = 0.001 · Mean difference (final values): -1.69 · 95% CI -2.69 to -0.68
SecondaryMean Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Hamilton Anxiety Rating Scale (HAM-A) Total Score for the Efficacy Sample Set

The HAM-A is utilized for the evaluation of anxiety symptoms. The HAM-A consists of 14 items. Each item is rated on a 0 to 4 scale. For all of these items, 0 is the "best" rating and 4 is the "worst" rating. If no item scores are missing, then the HAM-A total score is the sum of all 14 item scores. The possible total scores are from 0 to 56, with higher scores indicating worse anxiety symptoms.

Time frame:
Baseline and Week 14
Reported as:
Least squares mean · Units on a scale
Mean Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Hamilton Anxiety Rating Scale (HAM-A) Total Score for the Efficacy Sample Set
Units on a scaleBrexpiprazole (1mg) + ADTBrexpiprazole (3mg) + ADTPlacebo + ADT
Mean Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Hamilton Anxiety Rating Scale (HAM-A) Total Score for the Efficacy Sample Set-3.43 ± 0.31-3.89 ± 0.31-3.33 ± 0.32
Statistical analysis
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · ANCOVA · p = 0.8164 · Mean difference (final values): -0.1 · 95% CI -0.93 to 0.73
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · ANCOVA · p = 0.1939 · Mean difference (final values): -0.55 · 95% CI -1.39 to 0.28
SecondaryMean Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in HAM-A Total for the Efficacy Sample Per Final Protocol

The HAM-A is utilized for the evaluation of anxiety symptoms. The HAM-A consists of 14 items. Each item is rated on a 0 to 4 scale. For all of these items, 0 is the "best" rating and 4 is the "worst" rating. If no item scores are missing, then the HAM-A total score is the sum of all 14 item scores. The possible total scores are from 0 to 56, with higher score indicating worse anxiety symptoms.

Time frame:
Baseline and Week 14
Reported as:
Least squares mean · Units on a scale
Mean Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in HAM-A Total for the Efficacy Sample Per Final Protocol
Units on a scaleBrexpiprazole (1mg) + ADTBrexpiprazole (3mg) + ADTPlacebo + ADT
Mean Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in HAM-A Total for the Efficacy Sample Per Final Protocol-3.35 ± 0.32-3.96 ± 0.33-3.07 ± 0.33
Statistical analysis
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · ANCOVA · p = 0.5192 · Mean difference (final values): -0.28 · 95% CI -1.14 to 0.57
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · ANCOVA · p = 0.0443 · Mean difference (final values): -0.88 · 95% CI -1.75 to -0.02
SecondaryMean CGI-I Score at Each Trial Week Visit in Phase B for the Efficacy Sample Set

The efficacy of study medication was rated for each participant using the CGI-I. The study physician would rate the participant's total improvement whether or not it is due entirely to drug treatment. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.

Time frame:
Week 8 to Week 14
Reported as:
Mean · Units on a scale
Mean CGI-I Score at Each Trial Week Visit in Phase B for the Efficacy Sample Set
Units on a scaleBrexpiprazole (1mg) + ADTBrexpiprazole (3mg) + ADTPlacebo + ADT
Week 93.36 ± 0.683.4 ± 0.753.51 ± 0.67
Week 103.08 ± 0.853.09 ± 0.853.34 ± 0.85
Week 112.91 ± 0.822.99 ± 0.893.17 ± 0.88
Week 122.78 ± 0.872.81 ± 0.953.02 ± 0.95
Week 132.72 ± 0.872.73 ± 1.012.97 ± 1.00
Week 142.69 ± 0.892.66 ± 1.12.85 ± 1.01
Statistical analysis
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0248 · Mean difference (final values): -0.14 · 95% CI -0.26 to -0.02P-value and treatment difference (CI) are derived from Cochran-Mantel-Haenszel (CMH) row mean score differ test controlling for study center.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.1334 · Mean difference (final values): -0.1 · 95% CI -0.22 to 0.03P-value and treatment difference (CI) are derived from CMH row mean scores statistics controlling for study center.
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0009 · Mean difference (final values): -0.27 · 95% CI -0.42 to -0.11P-value and treatment difference (CI) are derived from CMH row mean score differ test controlling for study center.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0019 · Mean difference (final values): -0.24 · 95% CI -0.38 to -0.09P-value and treatment difference (CI) are derived from CMH row mean scores statistics controlling for study center
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0009 · Mean difference (final values): -0.26 · 95% CI -0.42 to -0.11P-value and treatment difference (CI) are derived from CMH row mean score differ test controlling for study center
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0254 · Mean difference (final values): -0.18 · 95% CI -0.34 to -0.02P-value and treatment difference (CI) are derived from CMH row mean score differ test controlling for study center.
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0035 · Mean difference (final values): -0.25 · 95% CI -0.41 to -0.08P-value and treatment difference (CI) are derived from CMH row mean score differ test controlling for study center.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0152 · Mean difference (final values): -0.21 · 95% CI -0.39 to -0.04P-value and treatment difference (CI) are derived from CMH row mean score differ test controlling for study center.
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.004 · Mean difference (final values): -0.25 · 95% CI -0.42 to -0.08P-value and treatment difference (CI) are derived from CMH row mean score differ test controlling for study center.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.013 · Mean difference (final values): -0.23 · 95% CI -0.42 to -0.05P-value and treatment difference (CI) are derived from CMH row mean score differ test controlling for study center.
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0755 · Mean difference (final values): -0.16 · 95% CI -0.33 to 0.02P-value and treatment difference (CI) are derived from CMH row mean score differ test controlling for study center.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0527 · Mean difference (final values): -0.2 · 95% CI -0.39 to 0P-value and treatment difference (CI) are derived from CMH row mean score differ test controlling for study center
SecondaryMean CGI-I Score at Each Trial Week Visit in Phase B for the Efficacy Sample Per Final Protocol

The efficacy of study medication was rated for each participant using the CGI-I. The study physician would rate the participant's total improvement whether or not it is due entirely to drug treatment. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.

Time frame:
Weeks 8, 9, 10, 11, 12, 13, and 14
Reported as:
Mean · Units on a scale
Mean CGI-I Score at Each Trial Week Visit in Phase B for the Efficacy Sample Per Final Protocol
Units on a scaleBrexpiprazole (1mg) + ADTBrexpiprazole (3mg) + ADTPlacebo + ADT
Week 93.39 ± 0.653.42 ± 0.743.54 ± 0.65
Week 103.1 ± 0.823.08 ± 0.843.35 ± 0.84
Week 112.93 ± 0.82.99 ± 0.893.19 ± 0.86
Week 122.8 ± 0.862.81 ± 0.943.06 ± 0.94
Week 132.75 ± 0.862.72 ± 13.01 ± 0.96
Week 142.71 ± 0.882.65 ± 1.092.9 ± 0.99
Statistical analysis
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0275 · Mean difference (final values): -0.14 · 95% CI -0.26 to -0.01P-value and treatment difference (CI) are derived from CMH row mean score differ test controlling for study center.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.1583 · Mean difference (final values): -0.09 · 95% CI -0.22 to 0.04P-value and treatment difference (CI) are derived from CMH row mean score differ test controlling for study center.
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0021 · Mean difference (final values): -0.25 · 95% CI -0.41 to -0.09P-value and treatment difference (CI) are derived from CMH row mean score differ test controlling for study center.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0018 · Mean difference (final values): -0.24 · 95% CI -0.4 to -0.09P-value and treatment difference (CI) are derived from CMH row mean score differ test controlling for study center.
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0011 · Mean difference (final values): -0.27 · 95% CI -0.43 to -0.11P-value and treatment difference (CI) are derived from CMH row mean score differ test controlling for study center.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0235 · Mean difference (final values): -0.19 · 95% CI -0.36 to -0.03P-value and treatment difference (CI) are derived from CMH row mean score differ test controlling for study center.
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0021 · Mean difference (final values): -0.27 · 95% CI -0.44 to -0.10P-value and treatment difference (CI) are derived from CMH row mean score differ test controlling for study center.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0111 · Mean difference (final values): -0.24 · 95% CI -0.42 to -0.05P-value and treatment difference (CI) are derived from CMH row mean score differ test controlling for study center.
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0030 · Mean difference (final values): -0.26 · 95% CI -0.44 to -0.09P-value and treatment difference (CI) are derived from CMH row mean score differ test controlling for study center.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0046 · Mean difference (final values): -0.28 · 95% CI -0.47 to -0.09P-value and treatment difference (CI) are derived from CMH row mean score differ test controlling for study center.
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0237 · Mean difference (final values): -0.21 · 95% CI -0.39 to -0.03P-value and treatment difference (CI) are derived from CMH row mean score differ test controlling for study center.
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0171 · Mean difference (final values): -0.25 · 95% CI -0.45 to -0.04P-value and treatment difference (CI) are derived from CMH row mean score differ test controlling for study center.
SecondaryPercentage of Participants With a MADRS Response During Phase B Relative to the End of Phase A (Week 8 Visit) for the Efficacy Sample Set

MADRS response was defined as \>=50 percent reduction in MADRS Total Score from end of Phase A (Week 8). The MADRS was utilized as an efficacy assessment of a participant's level of depression. The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place. The MADRS Total Score is the sum of ratings for all 10 items. The possible total scores are from 0 to 60, with higher values indicating worse outcome.

Time frame:
Weeks 8, 9, 10, 11, 12, 13, and 14
Reported as:
Number · Percentage of participants
Percentage of Participants With a MADRS Response During Phase B Relative to the End of Phase A (Week 8 Visit) for the Efficacy Sample Set
Percentage of participantsBrexpiprazole (1mg) + ADTBrexpiprazole (3mg) + ADTPlacebo + ADT
Week 94.50.452.8
Week 1010.26.195.05
Week 1113.310.68.72
Week 1216.915.510.1
Week 1318.218.615.6
Week 1423.122.115.1
Statistical analysis
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.5279 · Ratio of response rate: 1.37 · 95% CI 0.51 to 3.68CMH general association test controlling for trial site
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0141 · Ratio of response rate: 0.13 · 95% CI 0.02 to 0.94CMH general association test controlling for trial site
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0484 · Ratio of response rate: 1.92 · 95% CI 0.99 to 3.72CMH general association test controlling for trial site
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.5813 · Ratio of response rate: 1.23 · 95% CI 0.60 to 2.50CMH general association test controlling for trial site
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.1236 · Ratio of response rate: 1.51 · 95% CI 0.90 to 2.54CMH general association test controlling for trial site
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.4998 · Ratio of response rate: 1.21 · 95% CI 0.70 to 2.10CMH general association test controlling for trial site
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0365 · Ratio of response rate: 1.64 · 95% CI 1.03 to 2.61CMH general association test controlling for trial site
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0822 · Ratio of response rate: 1.52 · 95% CI 0.95 to 2.43CMH general association test controlling for trial site
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.4049 · Ratio of response rate: 1.19 · 95% CI 0.79 to 1.78CMH general association test controlling for trial site
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.2951 · Ratio of response rate: 1.23 · 95% CI 0.84 to 1.80CMH general association test controlling for trial site
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0248 · Ratio of response rate: 1.53 · 95% CI 1.06 to 2.20CMH general association test controlling for trial site
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0326 · Ratio of response rate: 1.51 · 95% CI 1.03 to 2.21CMH general association test controlling for trial site
SecondaryPercentage of Participants With a MADRS Response During Phase B Relative to the End of Phase A (Week 8 Visit) for the Efficacy Sample Per Final Protocol

MADRS response was defined as \>=50 percent reduction in MADRS Total Score from end of Phase A (Week 8). The MADRS was utilized as an efficacy assessment of a participant's level of depression. The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place. The MADRS Total Score is the sum of ratings for all 10 items. The possible total scores are from 0 to 60, with higher values indicating worse outcome.

Time frame:
Weeks 8, 9, 10, 11, 12, 13, and 14
Reported as:
Number · Percentage of participants
Percentage of Participants With a MADRS Response During Phase B Relative to the End of Phase A (Week 8 Visit) for the Efficacy Sample Per Final Protocol
Percentage of participantsBrexpiprazole (1mg) + ADTBrexpiprazole (3mg) + ADTPlacebo + ADT
Week 93.370.483.02
Week 107.586.14.93
Week 1113.311.38.37
Week 1216.616.410.3
Week 131819.214.3
Week 1423.22314.3
Statistical analysis
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.7993 · Ratio of response rate: 0.87 · 95% CI 0.30 to 2.55CMH general association test controlling for trial site
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0118 · Ratio of response rate: 0.11 · 95% CI 0.01 to 0.93CMH general association test controlling for trial site
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.2825 · Ratio of response rate: 1.50 · 95% CI 0.71 to 3.16CMH general association test controlling for trial site
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.6375 · Ratio of response rate: 1.20 · 95% CI 0.58 to 2.50CMH general association test controlling for trial site
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0923 · Ratio of response rate: 1.62 · 95% CI 0.92 to 2.82CMH general association test controlling for trial site
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.3812 · Ratio of response rate: 1.29 · 95% CI 0.73 to 2.30CMH general association test controlling for trial site
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0464 · Ratio of response rate: 1.63 · 95% CI 1.00 to 2.65CMH general association test controlling for trial site
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0490 · Ratio of response rate: 1.62 · 95% CI 1.00 to 2.64CMH general association test controlling for trial site
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.2124 · Ratio of response rate: 1.32 · 95% CI 0.85 to 2.06CMH general association test controlling for trial site
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.1078 · Ratio of response rate: 1.41 · 95% CI 0.93 to 2.14CMH general association test controlling for trial site
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0094 · Ratio of response rate: 1.69 · 95% CI 1.14 to 2.50CMH general association test controlling for trial site
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0162 · Ratio of response rate: 1.65 · 95% CI 1.09 to 2.50CMH general association test controlling for trial site
SecondaryPercentage of Participants With a MADRS Remission During Phase B Relative to the End of Phase A (Week 8) for the Efficacy Sample Set

MADRS remission was defined as a \< or equal to 10 and \> or equal to 50% reduction in MADRS Total Score from end of Phase A (Week 8). The MADRS was utilized as an efficacy assessment of a participant's level of depression. The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place. The MADRS Total Score is the sum of ratings for all 10 items. The possible total scores are from 0 to 60, with higher values indicating worse outcome.

Time frame:
Weeks 8, 9, 10, 11, 12, 13 and 14
Reported as:
Number · Percentage of participants
Percentage of Participants With a MADRS Remission During Phase B Relative to the End of Phase A (Week 8) for the Efficacy Sample Set
Percentage of participantsBrexpiprazole (1mg) + ADTBrexpiprazole (3mg) + ADTPlacebo + ADT
Week 93.150.452.8
Week 1042.654.13
Week 118.446.195.5
Week 1211.18.855.96
Week 1310.712.89.17
Week 1415.113.711.9
Statistical analysis
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.9498 · Ratio of remission rate: 1.03 · 95% CI 0.37 to 2.90CMH general association test controlling for trial site
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0141 · Ratio of response rate: 0.13 · 95% CI 0.02 to 0.94CMH general association test controlling for trial site
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.8609 · Ratio of response rate: 0.93 · 95% CI 0.40 to 2.17CMH general association test controlling for trial site
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.2846 · Ratio of response rate: 0.59 · 95% CI 0.22 to 1.54CMH general association test controlling for trial site
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.2480 · Ratio of response rate: 1.50 · 95% CI 0.75 to 2.99CMH general association test controlling for trial site
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.7513 · Ratio of response rate: 1.13 · 95% CI 0.54 to 2.37CMH general association test controlling for trial site
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0554 · Ratio of response rate: 1.82 · 95% CI 0.99 to 3.35CMH general association test controlling for trial site
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.2409 · Ratio of response rate: 1.48 · 95% CI 0.76 to 2.87CMH general association test controlling for trial site
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.5538 · Ratio of response rate: 1.18 · 95% CI 0.69 to 2.02CMH general association test controlling for trial site
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.1743 · Ratio of response rate: 1.44 · 95% CI 0.85 to 2.41CMH general association test controlling for trial site
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.2843 · Ratio of response rate: 1.30 · 95% CI 0.81 to 2.07CMH general association test controlling for trial site
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.4640 · Ratio of response rate: 1.19 · 95% CI 0.74 to 1.92CMH general association test controlling for trial site
SecondaryPercentage of Participants With a MADRS Remission During Phase B Relative to the End of Phase A (Week 8) for the Efficacy Sample Per Final Protocol

MADRS remission was defined as a \< or equal to 10 and \> or equal to 50% reduction in MADRS Total Score from end of Phase A (Week 8). The MADRS was utilized as an efficacy assessment of a participant's level of depression. The MADRS consisted of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS total score were to be unevaluable if less than 8 of the 10 items were recorded. If 8 or 9 of the 10 items were recorded, the MADRS total score was the mean of the recorded items multiplied by 10 and then rounded of to the first decimal place. The MADRS Total Score is the sum of ratings for all 10 items. The possible total scores are from 0 to 60, with higher values indicating worse outcome.

Time frame:
Weeks 8, 9, 10, 11, 12, 13 and 14
Reported as:
Number · Percentage of participants
Percentage of Participants With a MADRS Remission During Phase B Relative to the End of Phase A (Week 8) for the Efficacy Sample Per Final Protocol
Percentage of participantsBrexpiprazole (1mg) + ADTBrexpiprazole (3mg) + ADTPlacebo + ADT
Week 91.920.483.02
Week 102.372.823.94
Week 118.066.575.42
Week 1210.49.396.4
Week 139.9513.18.37
Week 1414.714.110.8
Statistical analysis
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.3867 · Ratio of response rate: 0.60 · 95% CI 0.18 to 1.97CMH general association test controlling for trial site
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0118 · Ratio of response rate: 0.11 · 95% CI 0.01 to 0.93CMH general association test controlling for trial site
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.3200 · Ratio of response rate: 0.59 · 95% CI 0.21 to 1.66CMH general association test controlling for trial site
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.3266 · Ratio of response rate: 0.60 · 95% CI 0.23 to 1.62CMH general association test controlling for trial site
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.3027 · Ratio of response rate: 1.47 · 95% CI 0.70 to 3.10CMH general association test controlling for trial site
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.6960 · Ratio of response rate: 1.17 · 95% CI 0.54 to 2.52CMH general association test controlling for trial site
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.1368 (CMH general association test controlling for trial site) · Ratio of response rate: 1.62 · 95% CI 0.86 to 3.07
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.2387 · Ratio of response rate: 1.48 · 95% CI 0.76 to 2.89CMH general association test controlling for trial site
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.4498 · Ratio of response rate: 1.26 · 95% CI 0.69 to 2.28CMH general association test controlling for trial site
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.1009 · Ratio of response rate: 1.60 · 95% CI 0.91 to 2.82CMH general association test controlling for trial site
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.1499 · Ratio of response rate: 1.45 · 95% CI 0.87 to 2.41CMH general association test controlling for trial site
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.3012 · Ratio of response rate: 1.31 · 95% CI 0.78 to 2.18CMH general association test controlling for trial site
SecondaryPercentage of Participants With a CGI-I Response During Phase B Relative to the End of Phase A (Week 8 Visit) for the Efficacy Sample Set

A CGI-I response was defined as a CGI-I score of 1 (very much improved) or 2 (much improved).

Time frame:
Weeks 8, 9, 10, 11, 12, 13 and 14
Reported as:
Number · Percentage of participants
Percentage of Participants With a CGI-I Response During Phase B Relative to the End of Phase A (Week 8 Visit) for the Efficacy Sample Set
Percentage of participantsBrexpiprazole (1mg) + ADTBrexpiprazole (3mg) + ADTPlacebo + ADT
Week 99.4610.46.54
Week 1023.62313.3
Week 1128.430.121.6
Week 1235.138.129.4
Week 134043.428.9
Week 1441.847.836.7
Statistical analysis
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.2873 · Ratio of response rate: 1.41 · 95% CI 0.75 to 2.65CMH general association test controlling for trial site
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.2677 · Ratio of response rate: 1.37 · 95% CI 0.79 to 2.36CMH general association test controlling for trial site
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0031 · Ratio of response rate: 1.80 · 95% CI 1.21 to 2.68CMH general association test controlling for trial site
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0066 · Ratio of response rate: 1.70 · 95% CI 1.15 to 2.50CMH general association test controlling for trial site
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0665 · Ratio of response rate: 1.34 · 95% CI 0.98 to 1.83CMH general association test controlling for trial site
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0250 · Ratio of response rate: 1.41 · 95% CI 1.05 to 1.91CMH general association test controlling for trial site
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.2224 · Ratio of response rate: 1.18 · 95% CI 0.90 to 1.54CMH general association test controlling for trial site
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0369 · Ratio of response rate: 1.31 · 95% CI 1.01 to 1.68CMH general association test controlling for trial site
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0179 · Ratio of response rate: 1.36 · 95% CI 1.05 to 1.75CMH general association test controlling for trial site
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0011 · Ratio of response rate: 1.49 · 95% CI 1.17 to 1.89CMH general association test controlling for trial site
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.3249 · Ratio of response rate: 1.12 · 95% CI 0.89 to 1.41CMH general association test controlling for trial site
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0122 · Ratio of response rate: 1.33 · 95% CI 1.06 to 1.66CMH general association test controlling for trial site
SecondaryPercentage of Participants With a CGI-I Response During Phase B Relative to the End of Phase A (Week 8 Visit) for the Efficacy Sample Per Final Protocol

A CGI-I response was defined as a CGI-I score of 1 (very much improved) or 2 (much improved).

Time frame:
Weeks, 8, 9, 10, 11, 12, 13, and 14
Reported as:
Number · Percentage of participants
Percentage of Participants With a CGI-I Response During Phase B Relative to the End of Phase A (Week 8 Visit) for the Efficacy Sample Per Final Protocol
Percentage of participantsBrexpiprazole (1mg) + ADTBrexpiprazole (3mg) + ADTPlacebo + ADT
Week 97.699.525.53
Week 1021.82312.3
Week 1127.53019.7
Week 1234.13827.6
Week 1338.944.127.1
Week 1441.248.434
Statistical analysis
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.5836 · Ratio of response rate: 1.22 · 95% CI 0.60 to 2.49CMH general association test controlling for trial site
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.3792 · Ratio of response rate: 1.31 · 95% CI 0.73 to 2.37CMH general association test controlling for trial site
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Ratio of response rate · p = 0.0101 · Ratio of response rate: 1.77 · 95% CI 1.14 to 2.74CMH general association test controlling for trial site
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0065 · Ratio of response rate: 1.75 · 95% CI 1.17 to 2.63CMH general association test controlling for trial site
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0526 · Ratio of response rate: 1.41 · 95% CI 1.00 to 1.99CMH general association test controlling for trial site
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0156 · Ratio of response rate: 1.51 · 95% CI 1.08 to 2.11CMH general association test controlling for trial site
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.1689 · Ratio of response rate: 1.22 · 95% CI 0.92 to 1.63CMH general association test controlling for trial site
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0231 · Ratio of response rate: 1.37 · 95% CI 1.04 to 1.80CMH general association test controlling for trial site
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0175 · Ratio of response rate: 1.40 · 95% CI 1.06 to 1.84CMH general association test controlling for trial site
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0004 · Ratio of response rate: 1.59 · 95% CI 1.22 to 2.07CMH general association test controlling for trial site
  • Brexpiprazole (1mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.1396 · Ratio of response rate: 1.21 · 95% CI 0.94 to 1.55CMH general association test controlling for trial site
  • Brexpiprazole (3mg) + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0016 · Ratio of response rate: 1.46 · 95% CI 1.15 to 1.86CMH general association test controlling for trial site

Adverse events

Collected over AEs were captured from randomization to double-blind treatment at Week 8 to Follow-up 30 (+ 2) days after last dose of study medication.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brexpiprazole (1mg + ADT)—1/226 (0.4%)63/226 (27.9%)
Brexpiprazole (3mg + ADT)—1/229 (0.4%)72/229 (31.4%)
Placebo + ADT—0/220 (0%)29/220 (13.2%)
Most frequent serious events
Most frequent serious events
EventBrexpiprazole (1mg + ADT)Brexpiprazole (3mg + ADT)Placebo + ADT
PneumoniaInfections and infestations1/2260/2290/220
EpilepsyNervous system disorders0/2261/2290/220
Most frequent other events
Most frequent other events
EventBrexpiprazole (1mg + ADT)Brexpiprazole (3mg + ADT)Placebo + ADT
AkathisiaNervous system disorders10/22631/2295/220
HeadacheNervous system disorders21/22614/22917/220
NasopharyngitisInfections and infestations15/2267/2294/220
Weight increasedInvestigations15/22613/2292/220
SomnolenceNervous system disorders9/22613/2291/220
TremorNervous system disorders9/22612/2297/220

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Brexpiprazole (1mg + ADT)Brexpiprazole (3mg + ADT)Placebo + ADTTotal
Mean45.7 ± 11.644.5 ± 11.246.6 ± 11.045.6 ± 11.3
Sex: Female, Male
Sex: Female, Male(Participants)Brexpiprazole (1mg + ADT)Brexpiprazole (3mg + ADT)Placebo + ADTTotal
Female158156146460
Male687475217
09

Study locations

71 sites
  • Research Site
    Birmingham, Alabama, United States
  • Research Site
    Costa Mesa, California, United States
  • Research Site
    Glendale, California, United States
  • Research Site
    Orange, California, United States
  • Research Site
    San Diego, California, United States
  • Research Site
    Temecula, California, United States
  • Research Site
    Jacksonville Beach, Florida, United States
  • Research Site
    Jacksonville, Florida, United States
  • Research Site
    Miami Springs, Florida, United States
  • Research Site
    Tampa, Florida, United States
  • Research Site
    Winter Park, Florida, United States
  • Research Site
    Atlanta, Georgia, United States
  • Research Site
    Smyrna, Georgia, United States
  • Research Site
    Chicago, Illinois, United States
  • Research Site
    Oak Brook, Illinois, United States
  • Research Site
    Lafayette, Indiana, United States
  • Research Site
    Owensboro, Kentucky, United States
  • Research Site
    Baltimore, Maryland, United States
  • Research Site
    Haverhill, Massachusetts, United States
  • Research Site
    Weymouth, Massachusetts, United States
  • Research Site
    Rochester Hills, Michigan, United States
  • Research Site
    Creve Coeur, Missouri, United States
  • Research Site
    Las Vegas, Nevada, United States
  • Research Site
    Cherry Hill, New Jersey, United States
  • Research Site
    Toms River, New Jersey, United States
  • Research Site
    Brooklyn, New York, United States
  • Research Site
    Fresh Meadows, New York, United States
  • Research Site
    New York, New York, United States
  • Research Site
    Staten Island, New York, United States
  • Research Site
    Raleigh, North Carolina, United States
  • Research Site
    Beachwood, Ohio, United States
  • Research Site
    Cincinnati, Ohio, United States
  • Research Site
    Columbus, Ohio, United States
  • Research Site
    Oklahoma City, Oklahoma, United States
  • Research Site
    Portland, Oregon, United States
  • Salem, Oregon, United States
  • Research Site
    Norristown, Pennsylvania, United States
  • Research Site
    Philadelphia, Pennsylvania, United States
  • Research Site
    Lincoln, Rhode Island, United States
  • Research Site
    Columbia, South Carolina, United States
  • Research Site
    Memphis, Tennessee, United States
  • Research Site
    Austin, Texas, United States
  • Research Site
    Dallas, Texas, United States
  • Research Site
    Houston, Texas, United States
  • Research Site
    San Antonio, Texas, United States
  • Research Site
    Witchita Falls, Texas, United States
  • Research Site
    Charlottesville, Virginia, United States
  • Research Site
    Herndon, Virginia, United States
  • Research Site
    Bellevue, Washington, United States
  • Research Site
    Spokane, Washington, United States
  • Research Site
    Brown Deer, Wisconsin, United States
  • Research Site
    Middleton, Wisconsin, United States
  • Research Site
    Toronto, Ontario, Canada
  • Research Site
    Pointe-Claire, Quebec, Canada
  • Research Site
    Wurzburg, Bavaria, Germany
  • Research Site
    Stralsund, Mecklenburg-Vorpommern, Germany
  • Research Site
    Bochum, NRW, Germany
  • Research Site
    Achim, Germany
  • Research Site
    Nyiregyhaza, Szabolcs Szatmar Bereg, Hungary
  • Research Site
    Budapest, Hungary
  • Research Site
    Gyor, Hungary
  • Research Site
    Bucharest, Romania
  • Research Site
    Lasi, Romania
  • Research Site
    Targu Mures, Romania
  • Research Site
    Moscow, Russian Federation
  • Research Site
    Rostov on Don, Russian Federation
  • Research Site
    Saint Petersburg, Russian Federation
  • Research Site
    Chenigiv, Ukraine
  • Research Site
    Kharkiv, Ukraine
  • Research Site
    Kiev, Ukraine
  • Research Site
    Poltava, Ukraine
10

References and documents

Publications

  • Newcomer JW, Eriksson H, Zhang P, Meehan SR, Weiss C. Changes in Metabolic Parameters and Body Weight in Patients With Major Depressive Disorder Treated With Adjunctive Brexpiprazole: Pooled Analysis of Phase 3 Clinical Studies. J Clin Psychiatry. 2019 Oct 1;80(6):18m12680. doi: 10.4088/JCP.18m12680. PubMed 31577867 ↗
  • Hobart M, Zhang P, Weiss C, Meehan SR, Eriksson H. Adjunctive Brexpiprazole and Functioning in Major Depressive Disorder: A Pooled Analysis of Six Randomized Studies Using the Sheehan Disability Scale. Int J Neuropsychopharmacol. 2019 Mar 1;22(3):173-179. doi: 10.1093/ijnp/pyy095. PubMed 30508090 ↗
  • McIntyre RS, Weiller E, Zhang P, Weiss C. Brexpiprazole as adjunctive treatment of major depressive disorder with anxious distress: Results from a post-hoc analysis of two randomised controlled trials. J Affect Disord. 2016 Sep 1;201:116-23. doi: 10.1016/j.jad.2016.05.013. Epub 2016 May 12. PubMed 27208498 ↗
  • Thase ME, Youakim JM, Skuban A, Hobart M, Zhang P, McQuade RD, Nyilas M, Carson WH, Sanchez R, Eriksson H. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. J Clin Psychiatry. 2015 Sep;76(9):1232-40. doi: 10.4088/JCP.14m09689. PubMed 26301771 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2011, a primary completion of Aug 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2016, 2 years 5 months after primary completion. A results delay was requested in Oct 2014.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2011
First posted
May 25, 2011
Start
Jun 2011
Primary completionActual
Aug 2013
CompletionActual
Sep 2013
Results delay requested
Oct 14, 2014
Results first posted
Jan 1, 2016
Last update
Jan 1, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 1, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01360632
Responsible party
Sponsor
First posted
May 25, 2011
Start date
Jun 2011
Primary completion
Aug 2013
Completion
Sep 2013
Results posted
Jan 1, 2016
Last update
Jan 1, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Brexpiprazole · Antiandrogens

Start the discussion